US 11,963,942 B2
Oral taxane compositions and methods
Denise S. B. Chan, Hong Kong (CN); Ming Tsung Lee, Hong Kong (CN); Weng Li Yoon, Hong Kong (CN); and Johnson Yiu-Nam Lau, Newport Beach, CA (US)
Assigned to Health Hope Pharma Ltd, Kowloon (HK)
Filed by Athenex HK Innovative Limited, Hong Kong (CN)
Filed on Oct. 13, 2020, as Appl. No. 17/069,557.
Application 17/069,557 is a continuation of application No. 15/277,890, filed on Sep. 27, 2016, granted, now 10,835,511.
Claims priority of provisional application 62/234,868, filed on Sep. 30, 2015.
Prior Publication US 2021/0023042 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/337 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 9/48 (2006.01); A61K 31/4725 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01)
CPC A61K 31/337 (2013.01) [A61K 9/0053 (2013.01); A61K 9/1075 (2013.01); A61K 9/4858 (2013.01); A61K 31/4725 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method of treating cancer, comprising orally administering a pharmaceutical composition to an individual in need of treatment for cancer, wherein the pharmaceutical composition comprises a taxane solution consisting of the taxane and a surfactant mixture consisting of a first surfactant that is polysorbate 80 and a second surfactant that is propane-1,2,3-triol-oxirane, wherein the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is from 65:35 to 80:20 by weight, wherein the first surfactant and the second surfactant comprise at least 90% of the pharmaceutical composition by weight, and wherein the pharmaceutical composition is effective to form a micellar suspension.